US 11,951,167 B2
Targeted liposomes
Esther H. Chang, Potomac, MD (US); SangSoo Kim, Gaithersburg, MD (US); and Antonina Rait, Rockville, MD (US)
Assigned to GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed by GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed on Feb. 5, 2021, as Appl. No. 17/168,614.
Application 17/168,614 is a division of application No. 14/030,563, filed on Sep. 18, 2013, abandoned.
Claims priority of provisional application 61/767,453, filed on Feb. 21, 2013.
Claims priority of provisional application 61/702,796, filed on Sep. 19, 2012.
Prior Publication US 2021/0205456 A1, Jul. 8, 2021
Int. Cl. A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01)
CPC A61K 45/06 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1271 (2013.01); A61K 9/1272 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A method of treating a brain cancer in a patient, comprising:
administering via intravenous administration to the patient a targeted temozolomide cationic liposome complex, wherein the targeted temozolomide cationic liposome complex comprises:
(a) a cationic liposome comprising 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE);
(b) temozolomide; and
(c) an anti-transferrin receptor single chain Fv (TfRscFv) directly complexed with, but not chemically conjugated to, the cationic liposome;
delivering the targeted temozolomide cationic liposome complex across the blood-brain barrier of the patient;
delivering the temozolomide to the brain cancer; and
inducing growth inhibition and/or regression of the brain cancer.